Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Barbarich et al.1 report the potential benefits of olanzapine
in treating anorexia nervosa. I disagree with their results
and conclusions for the following reasons.
The study’s small sample size of 17 patients, 12 of whom
completed the study, could result in a type II error. That 71% of
patients completed the study is not “noteworthy,” as the authors
claim​